These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38287391)

  • 1. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis.
    Lin W; Wang JX; Liu YJ
    Syst Rev; 2024 Jan; 13(1):46. PubMed ID: 38287391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
    J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elafibranor: First Approval.
    Blair HA
    Drugs; 2024 Sep; 84(9):1143-1148. PubMed ID: 39110316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis].
    Feng BL; Yu HH; Shen W
    Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):304-311. PubMed ID: 31082343
    [No Abstract]   [Full Text] [Related]  

  • 5. Bezafibrate for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD009145. PubMed ID: 22259000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.
    Zhang Y; Li S; He L; Wang F; Chen K; Li J; Liu T; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Xia Y; Zhou Y; Lu J; Guo C
    Drug Des Devel Ther; 2015; 9():2757-66. PubMed ID: 26045661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
    Khakoo NS; Sultan S; Reynolds JM; Levy C
    Dig Dis Sci; 2023 Apr; 68(4):1559-1573. PubMed ID: 36180756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
    Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additional fibrate treatment in UDCA-refractory PBC patients.
    Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
    Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales.
    Colapietro F; Gershwin ME; Lleo A
    J Transl Autoimmun; 2023; 6():100188. PubMed ID: 36684809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review.
    Li X; Liao M; Pan Q; Xie Q; Yang H; Peng Y; Li Q; Qu J; Chai J
    Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1116-1122. PubMed ID: 32649329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.
    Zhang H; Li S; Feng Y; Zhang Q; Xie B
    Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
    Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
    J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis.
    Caines A; Trudeau S; Gordon SC
    Expert Opin Pharmacother; 2024 Aug; 25(11):1517-1523. PubMed ID: 39107982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
    Ding D; Guo G; Liu Y; Zheng L; Jia G; Deng J; Sun R; Wang X; Guo C; Shang Y; Han Y
    Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K; Tanaka H; Haruno M
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis.
    Zhu GQ; Shi KQ; Huang S; Huang GQ; Lin YQ; Zhou ZR; Braddock M; Chen YP; Zheng MH
    Medicine (Baltimore); 2015 Mar; 94(11):e609. PubMed ID: 25789951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.